Gene therapy using vector-mediated transfer of prodrug activating genes is a promising treatment approach for malignant tumors. As demonstrated recently, the novel prodrug activating gene coding for rabbit cytochrome P450 4B1 (CYP4B1) is able to induce tumor cell death at low micromolar concentrations in glioblastoma cells after treatment with the prodrug 4-ipomeanol (4-IM) in vitro and in vivo. The rabbit CYP4B1 converts this prodrug and other furane analogs and aromatic amines, such as 2-aminoanthracene, to highly toxic alkylating metabolites, whereas the human isoenzyme exhibits only minimal enzymatic activity. In the present study, the cDNA encoding rabbit CYP4B1 was used for pharmacogene therapy of hepatocellular carcinoma (HCC). Cell clones derived from the human HCC cell lines Hep3B, HuH-7, and HepG2 and stably expressing the chimeric protein CYP4B1-EGFP (the CYP4B1 coding sequence fused to the enhanced green fluorescent protein (EGFP) gene) were selected. HCC clones expressing EGFP served as controls. 4-IM rapidly induced tumor cell death in CYP4B1-EGFP-expressing clones at low concentrations (a 50% lethal dose of between 0.5 and 2 g/mL). No signs of toxicity were found in control cells expressing EGFP even at high prodrug concentrations (20 g/mL). Cell death occurred by apoptosis and was independent of functional p53. A pronounced direct bystander effect was observed in Hep3B cells, whereas bystander HepG2 and HuH-7 cells were highly resistant to toxic 4-IM metabolites. These results demonstrate that the CYP4B1/4-IM system efficiently and rapidly induces cell death in HCC cells, and that a cell line-specific mechanism may exist that limits the extent of the bystander effect of this novel prodrug activating system.
H epatocellular carcinoma (HCC) is a prevalent malignant tumor with increasing incidence worldwide, 1 frequently developing as a consequence of liver cirrhosis. The major risk factors include chronic infection with hepatitis B and hepatitis C viruses and exposure to aflatoxins. 2, 3 HCC is generally highly resistant to chemotherapy and irradiation. Despite a variety of treatment options, including surgical resection, chemoembolization, percutaneous injection of ethanol or acetic acid, and liver transplantation, which demonstrated some benefits for patients with small solitary tumors, the prognosis of the majority of patients with larger or multifocal HCCs is poor. 4 -6 It is believed that molecular changes occurring during carcinogenesis, such as overexpression of the multidrug resistance gene (MDR-1) and the loss or mutation of tumor suppressor genes (e.g., p53) may allow tumor cell populations to become resistant to cytotoxic agents. [7] [8] [9] [10] Gene therapy may offer novel strategies for the treatment of HCC, such as the expression of prodrug activating enzymes in tumor cells that are able to locally convert a prodrug with low systemic toxicity into highly toxic agents. 11 The aim of this strategy is to increase the concentration of the corresponding active anti-cancer agent within the tumor, combined with low toxicity in normal tissues after systemic prodrug administration. The killing of nontransduced tumor cells in the proximity of transgene-expressing cells (the bystander effect) may amplify the toxicity of prodrug activating genes. Recent studies suggested that HCC cells expressing the herpes simplex thymidine kinase (TK) gene may become highly sensitive to the antiviral drug ganciclovir 12, 13 and also demonstrated the efficiency of the cytosine deaminase/5-fluorcytosine system for the in vitro and in vivo treatment of experimental HCC.
14 Furthermore, the combination of two therapeutic transgenes seems to improve the therapeutic efficiency of antitumoral gene therapy. [15] [16] [17] [18] This emphasizes the importance of the ongoing search for novel therapeutic genes and the assessment of their therapeutic efficiency in different tumor types.
Recently, a novel, highly potent prodrug activating enzyme, rabbit cytochrome P450 4B1 (CYP4B1), was established for the treatment of malignant glioma.
19 CYP4B1 converts the naturally occurring mold toxin 1-(3-furyl)-4-hydroxy-1-pentanone (4-ipomeanol (4-IM)) and the aromatic amine 2-aminoanthracene (2-AA) into highly toxic alkylating metabolites. 20 The human CYP4B1 isozyme is expressed in the liver and lung, but its metabolic activity toward the prodrug 4-IM is Ͻ1% of the rate of rabbit CYP4B1. 21 Expression of rabbit CYP4B1 in rat and human glioma cell lines rendered these cells highly sensitive to the prodrugs 4-IM and 2-AA. Furthermore, CYP4B1 induced a potent bystander effect and demonstrated therapeutic potential in vivo. 19 These promising results obtained with the CYP4B1/ 4-IM system in the glioma model led us to investigate its therapeutic potential for gene therapy of HCC. The present study extends the knowledge of the therapeutic efficiency of the CYP4B1/4-IM system and demonstrates the importance of tumor type-specific examination of novel therapeutic genes. 
MATERIALS AND METHODS

Prodrug
Cell lines
The human HCC cell lines HuH-7, HepG2, and Hep3B were obtained from the American Type Culture Collection (Manassas, Va) and maintained in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY) supplemented with 10% heat inactivated fetal bovine sera (Sigma, St. Louis, Mo), nonessential amino acids (Life Technologies), 50 U/mL penicillin G, and 50 g/mL streptomycin (Life Technologies) at 37°C in a humidified atmosphere of 7% CO 2 .
Generation of cell clones expressing enhanced green fluorescent protein (EGFP) and CYP4B1-EGFP HuH-7, Hep3B, and HepG2 cells were cultured in 100-mm dishes and transfected with 10 g of plasmid DNA (pEGFP-N3; Clontech Laboratories, Palo Alto, Calif) or pCYP4B1-EGFP 22 ( Fig 1A) complexed with cationic liposomes (Ge #67; Genzyme, Framingham, Mass) in 3 mL of serum-free medium (OptiMem; Life Technologies). After a 5-hour incubation, cells were washed twice with serum-free medium and cultured in complete Dulbecco's modified Eagle's medium. After 48 hours, cells were trypsinized and seeded at ϳ1 ϫ 10 5 cells per 250-mm dish. G418-resistant clones were selected using predetermined concentrations of G418 for each of the HCC cell lines. The expression of the autofluorescent proteins EGFP and CYP4B1-EGFP (Fig 1B) allowed fluorescent microscopic screening of the G418-resistant clones for expression level and monoclonality. We used a fluorescence microscope (Nikon Labophot; Nikon, Garden City, NY) equipped with the episcopic fluorescence attachment EF-D and a 510-nm filter. Monoclonal fluorescent colonies that were resistant to G418 were isolated and expanded for further use.
Immunoblot analysis
A mouse monoclonal antibody (mAb) against GFP (Clontech) and goat polyclonal anti-CYP4B1 anti-serum 23 were used for the determination of EGFP and CYP4B1-EGFP expression by Western blot analysis. Cell lysates were prepared in icecold Triton lysis buffer (50 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.5), 1% Triton X-100, 2 mM ethyleneglycol-bis(aminoethyl ester)-N,N,NЈ,NЈ-tetraacetic acid, 10 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride, 25 g/mL aprotinin, 3.5 g/mL pepstatin A, and 25 g/mL leupeptin), and the protein concentration was determined (protein assay; Bio-Rad, Hercules, Calif). Samples containing 50 g of total protein were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred onto Immobilon-P membranes (Millipore, Bedford, Mass). Immunoblotting was performed using predetermined optimal dilutions of primary and horseradish peroxidase-conjugated secondary antibodies (Abs) (Amersham, Chicago, Ill) followed by the enhanced chemiluminescence technique (Super Signal; Pierce, Rockford, Ill).
Detection of the cleavage of poly(ADP-ribose)polymerase (PARP) by caspase 3, which occurs specifically during apoptosis and represents a common final step in the activation of many different apoptotic pathways, was determined by immu- noblot using an anti-PARP mAb (Biomol, Plymouth Meeting, Penn). Approximately 1 ϫ 10 5 cells were harvested in Laemmli sample buffer and boiled for 5 minutes, followed by SDSpolyacrylamide gel electrophoresis. Immunoblot with anti-PARP Abs was performed as described above.
Cell viability assays
Crystalvioletstaining,3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay, and automated cell counting were used to measure cell viability. For the crystal violet assay, cells were grown in 96-well microtiter plates. After removal of the culture medium, cells were washed once with phosphate-buffered saline (PBS) followed by staining with a solution containing 0.75% crystal violet, 50% ethanol, 0.25% NaCl, and 1.75% formaldehyde for 10 minutes at 20°C. Cells were then washed thoroughly with water and air-dried. The dye was then eluted with 200 L of PBS containing 1% SDS. Cell viability was measured at 595 nm on an automated enzymelinked immunosorbent assay reader, where the optical density (OD) is directly proportional to the number of living cells. The viability of cells treated with prodrugs was calculated as the mean of quadruplicate OD values divided by the mean of quadruplicate OD values of identically cultured cells in the absence of prodrug (control cells) and was expressed as the percentage of control cells Ϯ SD. The OD values obtained from cells killed by 1% sodium azide were subtracted as background. The MTT assay was also used to measure cell proliferation. MTT dye (15 L, 5 mg/mL; Sigma) in 150 L of culture medium was added to cells grown in microtiter plates. After incubation for 1-4 hours and depending upon the intensity of the color reaction observed by microscopy, cells were rinsed with PBS and the dye was eluted in acidic isopropanol (0.04 M HCl in isopropanol). The OD readings at 450 nm were performed as described above. Determination of viable adherent cells was performed after vigorous washing with PBS to remove nonadherent cells followed by treatment with trypsin/EDTA to detach cells from the culture dishes. Cells were counted with an automated cell counter (Coulter Counter ZM; Coulter Electronics, Hialeah, Fla) or manually (after trypan blue exclusion) in a hemocytometer.
Cytotoxicity experiments
The HCC cells expressing CYP4B1-EGFP or EGFP were seeded in 96-well plates and exposed to increasing concentrations of 4-IM. A determination of cell viability was performed 48 hours after prodrug administration using the techniques described above. Equally seeded cells that received no prodrug served as controls. Results were expressed as a percentage of the viability of identically treated control cells. To evaluate the consequence of brief exposure (pulse) to 4-IM on cell growth (colony formation), cells were pulsed for 12 hours with the prodrug and subsequently washed twice with PBS, trypsinized, and replated on 100-mm dishes at a density of 5 ϫ 10 3 cells/dish in complete medium without prodrug. After 10 days, colonies were stained by crystal violet and examined by light microscopy. Colony growth was quantified by the crystal violet assay. For determination of bystander cell killing, CYP4B1-EGFP-expressing adherent cells were detached with trypsin/ EDTA, counted, and cocultured with EGFP-expressing cells or wild-type (wt) cells at various ratios. Cocultures were kept in 96-well plates and allowed to establish cell-to-cell contacts before 4-IM treatment. Determination of cell viability was performed in the presence or absence of the prodrug.
RESULTS
Expression of CYP4B1-EGFP and EGFP in HCC cells
After transient transfection with cationic liposomes, the expression of EGFP and CYP4B1-EGFP was examined using a fluorescence microscope. EGFP showed a relatively homogeneous intracellular localization and could be detected in the cytoplasm as well as in the nucleus of transfected HuH-7 cells (Fig 1B, left) . Expression of CYP4B1-EGFP (Fig 1B, right) exhibited a granular cytoplasmic pattern that is compatible with the expected microsomal localization of CYP4B1 as described previously for glioma cells.
22 G418-resistant stably transfected cell clones were analyzed for expression of the transgenes by fluorescence microscopy and by Western blot analysis. Using Abs against GFP (Fig 1C, lanes 1 and 2) , the expected 25-kDa protein was detected in cell lysates of control clones transfected with the EGFP plasmid, whereas in lysates of cell clones transfected with the pCYP4B1-EGFP plasmid, a 82-kDa protein corresponding to the expected size of the CYP4B1-EGFP fusion protein was detectable. A similarly sized protein (82 kDa) was detected in lysates of CYP4B1-EGFP-transfected cells using anti-rabbit CYP4B1 Abs (Fig 1C, lane  4) , but not in cell lysates of EGFP-transfected cell clones (Fig 1C, lane 3) . These results confirmed the correct expression of the fusion protein CYP4B1-EGFP and of EGFP in the respective HCC cell clones.
Analysis of cytotoxicity
Cell clones of all three HCC cell lines expressing CYP4B1-EGFP exhibited a high level of sensitivity toward 4-IM, which was measured 48 hours after initial exposure to the prodrug (Fig 2A) . The 50% lethal dose for the different clones was found to be in the range of 0.5 g/mL (HepG2, #11) to 1.8 g/mL (HuH-7, #16). No significant toxicity was observed in the control clones of all three HCC cell lines expressing EGFP treated with 4-IM concentrations up to 20 g/mL. Time course experiments showed that cell death occurred rapidly, as exposure of CYP4B1-EGFP-expressing HCC cells to 10 g/mL 4-IM resulted in killing of all tumor cells 24 -48 hours after prodrug administration (Fig 2B) . The sensitivity toward the prodrug directly correlated with the protein levels of intracellular CYP4B1-EGFP. This was demonstrated by the comparison of cellular toxicity toward 4-IM using various clones of the cell line HuH-7 expressing different levels of CYP4B1-EGFP (data not shown).
Using a pulse assay, the effect of a short (12 hours) exposure to 4-IM (3.5 g/mL) on the colony-forming ability of HCC cells was analyzed 10 days after the prodrug pulse (Fig 3) . Although the total number of colonies was not found to be significantly reduced, there was a marked reduction in the size of the resulting colonies. This observation indicates that even sublethal short-term exposure of CYP4B1-expressing HCC cells to 4-IM is sufficient to greatly impair the ability of surviving cells to proliferate.
Bystander effect
To analyze the ability of CYP4B1 to induce cell death in nonexpressing bystander cells, CYP4B1-EGFP-expressing HCC cells were cocultured with control cells of the corresponding HCC cell line stably expressing EGFP, or with wt cells. Cell-to-cell contacts were established previously by allowing the cocultured cells to grow to ϳ80% confluence (Fig 4) . Determination of cell viability after 48 hours of coculture in the presence of 10 g/mL 4-IM demonstrated a pronounced bystander effect for the HCC cell line Hep3B. In contrast, a high level of resistance to the bystander effect was observed for the cell lines HuH-7 and HepG2. Similar results were found when cells were cocultured for periods up to 5 days (data not shown).
Analysis of apoptosis
To determine the mechanism of cell death induced by the CYP4B1/4-IM system in HCC cells, CYP4B1-EGFP-expressing cells were treated with 10 g/mL 4-IM. Cell lysates obtained at several timepoints after prodrug administration were analyzed for the apoptosisspecific cleavage of PARP, a caspase 3 substrate, by immunoblot using anti-PARP Abs. The HCC cell lines used in this study represent different phenotypes with respect to the expression of functional p53 protein.
HepG2 cells express wt p53, whereas HuH-7 cells express a functionally defective p53 mutant protein; Hep3B cells have an extended deletion of both alleles of the p53 gene. 24 In all three HCC cell lines, marked cleavage of PARP was already detectable 12 hours after 4-IM administration, indicating early induction of the apoptotic machinery independent of the p53 status of the respective cell line (Fig 5) . These results demon- 
DISCUSSION
The use of rabbit CYP4B1 as a prodrug activating enzyme for gene therapy of malignant glioma has been reported recently. 19 It was demonstrated that expression of CYP4B1 in cultured glioma cells followed by prodrug exposure induced tumor cell death at low prodrug concentrations. Furthermore, treatment of glioma cells with the CYP4B1/4-IM prodrug activating system resulted in direct and distant bystander cell killing, and also proved to be efficient in vivo. Expression of CYP4B1 followed by the administration of prodrugs such as 4-IM or 2-AA induces the formation of alkylating metabolites that covalently bind to cellular macromolecules, resulting in extensive DNA-protein cross-linking and in DNA strand breakage leading to cell death by apoptosis. 25 Advantages of the CYP4B1/4-IM prodrug activating system observed in the glioma model include the low concentrations of prodrug needed to efficiently kill tumor cells expressing CYP4B1, the relatively low toxicity of the prodrug 4-IM 26, 27 in humans, the good penetration of the small lipophilic 4-IM molecule through the blood-brain barrier, 19 and the potent bystander effect. This bystander effect was not found to depend entirely upon cell-to-cell contact, 19 which is an important advantage in comparison with the widely used herpes simplex TK/ganciclovir system, where cell-to-cell contact is required for the induction of a bystander effect. 28 In the present study, the potential of this novel therapeutic gene for the treatment of HCC was characterized. HCC is a malignancy that exhibits a welldocumented resistance against various therapeutic strategies due to molecular alterations acquired during carcinogenesis, such as the loss of tumor suppressor genes or the overexpression of the multidrug resistance gene MDR-1. [7] [8] [9] [10] 29 The efficiency of the CYP4B1/4-IM prodrug activating system was evaluated in cell clones derived from three human HCC cell lines overexpressing a chimeric fusion protein of CYP4B1 with EGFP. It has been described previously that this fusion protein resembles the native CYP4B1 protein in its toxicity-inducing enzymatic activity in rodent and human glioma cell lines. 22 In our study, the use of the CYP4B1-EGFP fusion protein allowed screening of stable transfected cell clones by fluorescence microscopy for gene expression levels and for monoclonality. Expression of CYP4B1-EGFP rendered the tumor cells of the three human HCC cell lines highly sensitive to the prodrug 4-IM. The prodrug concentrations necessary to induce tumor cell death were low and were found to be in a range similar to those reported previously for rodent and human glioma cell lines. 19 Furthermore, transient sublethal exposure of HCC cells severely impaired the ability for colony formation, indicating that these cells were damaged irreversibly.
Cell death in HCC cells occurred by apoptosis within the first 48 hours after prodrug administration. Although the chemical structures and the precise mode of action of the toxic CYP4B1 converted metabolites of 4-IM are not well characterized, alkylation of DNA seems to be the main mode of toxicity. 21, 25, 30 Because the tumor suppressor gene p53 is involved in cell cycle control and in the induction of apoptosis after DNA damage, 31 the importance of p53 function for the mediation of the toxic effects of the CYP4B1/4-IM system in HCC cell lines with defined p53 status was examined. This is particularly important, because human HCCs were found to exhibit frequent mutations of the p53 gene 9, 32 and because p53-mediated apoptosis has been reported to be involved in the mechanism of HCC cell killing by chemotherapeutic agents. 24, 33 Thus, therapeutic ap- proaches that do not require a functional p53 gene are of interest for the treatment of HCC. Hep3B cells, which are p53-deficient (p53 Ϫ/Ϫ ), 34 were found to be as sensitive to CYP4B1/4-IM-induced toxicity as the cell line HepG2, which expresses wt p53. Furthermore, cell death in the p53 Ϫ/Ϫ Hep3B cell line, as well as in the HuH-7 cell line expressing a nonfunctional mutant p53 protein, occurred by apoptosis. Therefore, p53 function is not required for CYP4B1/4-IM-induced apoptosis in HCC cells.
One of the most important features of prodrug activating genes used in antitumoral gene therapy is the induction of a bystander effect, which allows for an efficient therapeutic effect under circumstances where only a small fraction of tumor cells expresses the therapeutic gene. 35 The previous observations in glioma cells suggest that there may exist two distinct mechanisms by which toxic metabolites of 4-IM are passed to bystander cells. 19 One of these mechanisms seems to require cell-to-cell contact, suggesting that metabolic cooperation mediated by gap junctions may be important for the CYP4B1/4-IM-induced bystander effect. However, there was also a weaker but significant bystander cell killing observed that was independent of cell contact, indicating that at least part of the bystander effect observed in glioma cells is mediated by diffusible toxic metabolites.
In contrast to the potent bystander effect induced by the CYP4B1/4-IM system in glioma cells, the bystander effect observed in HCC cell lines was found to show variations depending upon the cell line examined. Bystander cells of the cell line Hep3B were found to be highly susceptible to the toxicity of the CYP4B1/4-IM system, whereas bystander cells of the cell lines HuH-7 and HepG2 exhibited a high level of resistance. As Hep3B cells are negative for p53 protein expression, these results indicate that the p53 status of tumor cells does not influence the bystander effect induced by the CYP4B1/4-IM system. However, other cellular mechanisms may enable some cell lines to escape the CYP4B1/4-IM-induced bystander effect. In this regard, conjugation of 4-IM metabolites to cellular glutathione (GSH) may reduce their toxicity significantly. 36 Despite this mechanism of detoxification, cell death may still be induced in cells constitutively expressing CYP4B1 due to the continuous intracellular production of the alkylating metabolites during the time the cells are exposed to the prodrug. Released metabolites might be partially conjugated to GSH, which could explain a reduced toxicity for bystander cells. However, previous studies in glioma cells have demonstrated that blockade of GSH synthesis has no significant effect on CYP4B1-induced cellular toxicity. 19 Overexpression of the MDR-1 gene, which is known to be involved in reducing cellular toxicity in conventional chemotherapy of HCC, 8, 37 might also play a role in the reduction of the toxicity of 4-IM metabolites generated by CYP4B1. Therefore, further investigations will focus on the detailed characterization of such potential mechanisms involved in the reduction of the CYP4B1/4-IM-induced bystander effect in HCC cells. If such mechanisms could be modulated by additional therapeutic approaches, this could lead to an advanced therapeutic efficiency of this novel prodrug activating system.
The antitumoral effects of the CYP4B1/4-IM system also need to be evaluated in the context of the potential toxicity caused by the systemic administration of the prodrug. Previous studies performed in various species demonstrated 4-IM toxicity in the lung, kidney, and liver. 20, 38 In rodents, pulmonary toxicity was predominant and dose limiting. In contrast, two phase I human clinical trials revealed that dose-limiting 4-IM toxicity in humans was observed in the liver, suggesting that 4-IM may be preferentially activated in the liver in humans, or that human pulmonary tissue is more efficient in 4-IM detoxification. 26, 27 However, the observed hepatic toxicity in humans occurred only at very high doses of 4-IM corresponding at least to a 50% lethal dose in mice. 19 Nevertheless, the observation of potential hepatic toxicity mandates further studies evaluating the therapeutic range of 4-IM in patients with impaired liver function who may not be able to tolerate further compromise of their hepatic function. This is of particular importance in a high proportion of patients with HCC, who developed this malignancy as a consequence of underlying chronic liver disease. However, gene therapy using prodrug activating enzymes should render tumor cells highly sensitive to prodrug concentrations below the toxic doses observed for normal tissues. This is supported in the CYP4B1/4-IM system by the previous demonstration of the therapeutic efficiency in a glioma model in nude mice without apparent signs of toxicity, although this species is particularly susceptible to 4-IMinduced toxicity. 19 In conclusion, we have demonstrated that the CYP4B1/4-IM prodrug activating system effectively induces apoptotic cell death of HCC cells at low prodrug concentrations, but that cellular mechanisms may exist that limit the extent of the bystander effect in some HCC cell lines. To further evaluate the potential of CYP4B1/ 4-IM for pharmacogene therapy of HCC, its therapeutic efficiency needs to be characterized after direct gene delivery using an appropriate vector system in vitro and in vivo. Furthermore, the CYP4B1/4-IM system might be useful for augmentation of standard chemotherapy or gene therapy with other therapeutic genes, such as proapoptotic proteins or cytokines.
